Showing posts with label Chemistry. Show all posts
Showing posts with label Chemistry. Show all posts

Energy scenarios that actually provide useful decision-support tools for policymakers and investors

geekkeep.blogspot.com


Fulfilling the promise of the 2015 Paris Agreement on climate change—most notably the goal of limiting the rise in mean global surface temperature since preindustrial times to 2 degrees Celsius—will require a dramatic transition away from fossil fuels and toward low-carbon energy sources. To map out that transition, decision-makers routinely turn to energy scenarios, which use computational models to project changes to the energy mix that will be needed to meet climate and environmental targets. These models account for not only technological, economic, demographic, political, and institutional developments, but also the scope, timing, and stringency of policies to reduce greenhouse gas emissions and air pollution.
Energy scenarios provide useful decision-support tools for policymakers and investors
Credit: David Pilbrow/Flickr
Model-driven scenarios provide policymakers and investors with a powerful decision-support tool but should not be used as a decision-making tool due to several limitations. So argues a new study in the journal Energy and Environment by Sergey Paltsev, deputy director of the MIT Joint Program on the Science and Policy of Global Change and a senior research scientist for both the Joint Program and the MIT Energy Initiative. The study shows that overall, energy scenarios are useful for assessing policymaking and investment risks associated with different emissions reduction pathways, but tend to overestimate the degree to which future energy demand will resemble the past.
"Energy scenarios may not provide exact projections, but they are the best available tool to assess the magnitude of challenges that lie ahead," Paltsev observes in the study, a unique review of the value and limits of widely used energy scenarios that range from the International Energy Agency (IEA) World Energy Outlook, to the Joint Program's own annual Food, Water, Energy and Climate Outlook (which uses the MIT Economic Projection and Policy Analysis model), to a recent Intergovernmental Panel on Climate Change (IPCC) assessment report (AR5) presenting 392 energy scenarios aligned with the 2 C climate stabilization goal.
The study points out that because energy scenarios tend to vary widely in terms of the projections they produce for a given policy and the degree of uncertainty associated with those projections, it's not advisable to base an energy policy or investment decision on a single energy scenario. Taken collectively, however, energy scenarios can help bring into sharp focus a range of plausible futures—information decision-makers can use to assess the scale and cost of the technological changes needed to effect significant transformations in energy production and consumption. A careful review of multiple energy scenarios associated with a particular emissions pathway can provide a qualitative analysis of what's driving the results and the potential risks and benefits of a proposed policy or investment.
That said, projections in energy scenarios can sometimes be highly inaccurate due to factors that are difficult to anticipate.
For example, according to the study, which compared several energy scenario projections to historical observations, most energy scenarios do not account for sudden changes to the status quo. One of the greatest contributors to uncertainty in energy scenarios is the demand for low-emitting energy technologies, whose timing and scale of deployment—dependent on several economic and political factors—is highly unpredictable. Paltsev notes that the IEA constantly underestimates ; in its 2006 World Energy Outlook, the agency projected for 2020 a level of wind power generation that the world exceeded as early as 2013.
In addition, while energy scenarios have been largely successful in projecting the quantity of (e.g., the 1994 IEA World Energy Outlook's projection for 2010 was off by only 10 percent, despite highly disruptive developments such as the breakup of the Soviet Union, the world recession in 2008, and the emergence of the shale gas industry), most have been considerably off the mark when it comes to projecting energy prices (e.g., in 1993 dollars, the 1994 IEA WEO projected $28/barrel in 2010, but the actual price was $53/barrel).
Recognizing the steep challenge in projecting demand and prices for different energy sources in the midst of a dramatic energy transition, Paltsev emphasizes that governments should not try to pick a "winner"—a single energy technology that seems poised to reduce emissions singlehandedly—but rather adopt a strategy that targets emissions reductions from any energy source.
"Governments shouldn't pick the winners, because most likely that choice will be wrong," he says. "They should instead design policies such as carbon-pricing and emissions trading systems that are designed to achieve emissions reduction targets at the least cost."

credit: Mark Dwortzan 

Tumor suppressor key in maintaining stem cell status in muscle



A gene known to suppress tumor formation in a broad range of tissues plays a key role in keeping stem cells in muscles dormant until needed, a finding that may have implications for both human health and animal production, according to a Purdue University study.
Shihuan Kuang, professor of animal sciences, and Feng Yue, a postdoctoral researcher in Kuang's lab, reported their findings in two papers published in the journals Cell Reports and Nature Communications. The results suggest modifying expression of the PTEN gene could one day play a role in increasing in agricultural animals and improve therapies for muscle injuries in humans.
Muscle , called satellite cells, normally sit in a quiescent, or dormant, state until called upon to build muscle or repair a damaged muscle. Inability to maintain the quiescence would lead to a loss of satellite cells. As humans age, the number of satellite cells gradually declines and the remaining cells become less effective in regenerating muscles, resulting in muscle loss – a condition called sarcopenia.
Kuang and Yue, in the Nature Communications paper, explored the role tumor-suppressor gene PTEN plays in satellite cells. The PTEN gene encodes a protein that suppresses the growth signaling, thereby, limiting the growth of fast-growing tumor cells. Mutation of the PTEN gene is associated with many types of cancers, but how the gene functions in muscle stem cells is unknown.
To understand the function of a gene, the authors first wanted to know how the gene is expressed.
"This gene is highly expressed in the satellite cells when the cells are in the quiescent state. When they become differentiated, the PTEN level reduces," Yue said.
By knocking out the PTEN gene in resting satellite cells, the researchers found that satellite cells quickly differentiate and become muscle cells. So PTEN plays an essential role in keeping satellite cells in their quiescent state.
"You no longer have the stem cells once you knock out the gene," Kuang said.
In their Cell Reports paper, Kuang and Yue took a step further to examine PTEN function in proliferating stem cells. This time, they knocked out PTEN in embryonic progenitor cells, those that will later become muscle in the mouse. They found that as the mouse grew, muscle mass increased significantly—by as much as 40 percent in some muscles—over that of a normal mouse.
"That would be significant in an animal production point of view," Kuang said.
The increased muscle came with a cost, however. Besides creating muscle, those create satellite cells. Without PTEN, not only fewer satellite cells were created, but the resulting satellite cells cannot maintain dormancy, leading to an accelerated rate of depletion during aging.
The faster depletion of satellite cells during aging wouldn't matter much in an animal production scenario, Kuang said. Beef cattle, for example, are harvested before they age. The increase in muscle mass, however, would be a significant advantage in production efficiency.
The findings may lead to improvement in human health, the authors said. The ability to control the expression of PTEN could lead to therapies for quicker healing of muscle injuries.
"If you want to quickly boost up the stem cells to repair something, you need to suppress PTEN," Kuang said. "After that, you'd need to increase PTEN to return the cells back to quiescent state. If we could do that, you would suspect that the muscle would repair more quickly."
Knowing that PTEN also suppresses tumors in many types of tissues, the authors noted that the elimination of the gene did not cause tumor formation in the cells they studied. That suggests regulation of PTEN could be a feasible method for improving human health and animal agriculture.

Credit : Brian Wallheimer
The strength of real hair inspires new materials for body armor

The strength of real hair inspires new materials for body armor


Strength of hair inspires new materials for body armor
Researchers at the University of California San Diego investigate why hair is incredibly strong and resistant to breaking. Credit: iStock.com/natevplas
In a new study, researchers at the University of California San Diego investigate why hair is incredibly strong and resistant to breaking. The findings could lead to the development of new materials for body armor and help cosmetic manufacturers create better hair care products.
Hair has a strength to weight ratio comparable to steel. It can be stretched up to one and a half times its original length before breaking. "We wanted to understand the mechanism behind this extraordinary property," said Yang (Daniel) Yu, a nano-engineering Ph.D. student at UC San Diego and the first author of the study.
"Nature creates a variety of interesting materials and architectures in very ingenious ways. We're interested in understanding the correlation between the structure and the properties of biological materials to develop synthetic materials and designs—based on nature—that have better performance than existing ones," said Marc Meyers, a professor of mechanical engineering at the UC San Diego Jacobs School of Engineering and the lead author of the study.
In a study published online in Dec. in the journal Materials Science and Engineering C, researchers examined at the nano-scale level how a strand of human behaves when it is deformed, or stretched. The team found that hair behaves differently depending on how fast or slow it is stretched. The faster hair is stretched, the stronger it is. "Think of a highly viscous substance like honey," Meyers explained. "If you deform it fast it becomes stiff, but if you deform it slowly it readily pours."
Hair consists of two main parts—the cortex, which is made up of parallel fibrils, and the matrix, which has an amorphous (random) structure. The matrix is sensitive to the speed at which hair is deformed, while the cortex is not. The combination of these two components, Yu explained, is what gives hair the ability to withstand high stress and strain.
And as hair is stretched, its structure changes in a particular way. At the nano-scale, the cortex fibrils in hair are each made up of thousands of coiled spiral-shaped chains of molecules called alpha helix chains. As hair is deformed, the alpha helix chains uncoil and become pleated sheet structures known as beta sheets. This structural change allows hair to handle up a large amount deformation without breaking.
This structural transformation is partially reversible. When hair is stretched under a small amount of strain, it can recover its original shape. Stretch it further, the structural transformation becomes irreversible. "This is the first time evidence for this transformation has been discovered," Yu said.
"Hair is such a common material with many fascinating properties," said Bin Wang, a UC San Diego PhD alumna and co-author on the paper. Wang is now at the Shenzhen Institutes of Advanced Technology in China continuing research on hair.
The team also conducted stretching tests on hair at different humidity levels and temperatures. At higher humidity levels, hair can withstand up to 70 to 80 percent deformation before breaking. Water essentially "softens" hair—it enters the matrix and breaks the sulfur bonds connecting the filaments inside a strand of hair. Researchers also found that hair starts to undergo permanent damage at 60 degrees Celsius (140 degrees Fahrenheit). Beyond this temperature, hair breaks faster at lower stress and strain.
"Since I was a child I always wondered why hair is so strong. Now I know why," said Wen Yang, a former postdoctoral researcher in Meyers' research group and co-author on the paper.
The team is currently conducting further studies on the effects of water on the properties of . Moving forward, the team is investigating the detailed mechanism of how washing hair causes it to return to its original shape.
Combining  quantum physics and photosynthesis to make discovery that could lead to highly efficient solar cells

Combining quantum physics and photosynthesis to make discovery that could lead to highly efficient solar cells


Physics, photosynthesis and solar cells
In a light harvesting quantum photocell, particles of light (photons) can efficiently generate electrons. When two absorbing channels are used, solar power entering the system through the two absorbers (a and b) efficiently generates power …more
A University of California, Riverside assistant professor has combined photosynthesis and physics to make a key discovery that could help make solar cells more efficient. The findings were recently published in the journal Nano Letters.
Nathan Gabor is focused on experimental condensed matter physics, and uses light to probe the fundamental laws of quantum mechanics. But, he got interested in photosynthesis when a question popped into his head in 2010: Why are plants green? He soon discovered that no one really knows.
During the past six years, he sought to help change that by combining his background in physics with a deep dive into biology.
He set out to re-think by asking the question: can we make materials for solar cells that more efficiently absorb the fluctuating amount of energy from the sun. Plants have evolved to do this, but current affordable solar cells - which are at best 20 percent efficient - do not control these sudden changes in solar power, Gabor said. That results in a lot of wasted energy and helps prevent wide-scale adoption of solar cells as an energy source.
Gabor, and several other UC Riverside physicists, addressed the problem by designing a new type of quantum photocell, which helps manipulate the flow of energy in . The design incorporates a heat engine photocell that absorbs photons from the sun and converts the photon energy into electricity.
Surprisingly, the researchers found that the quantum heat engine photocell could regulate solar power conversion without requiring active feedback or adaptive control mechanisms. In conventional photovoltaic technology, which is used on rooftops and solar farms today, fluctuations in solar power must be suppressed by voltage converters and feedback controllers, which dramatically reduce the overall efficiency.
Physics, photosynthesis and solar cells
Nathan Gabor's Laboratory of Quantum Materials Optoelectronics utilizes infrared laser spectroscopy techniques to explore natural regulation in quantum photocells composed of two-dimensional semiconductors. Credit: Max Grossnickle and QMO Lab
The goal of the UC Riverside teams was to design the simplest photocell that matches the amount of solar power from the sun as close as possible to the average power demand and to suppress energy fluctuations to avoid the accumulation of excess energy.
The researchers compared the two simplest quantum mechanical photocell systems: one in which the photocell absorbed only a single color of light, and the other in which the photocell absorbed two colors. They found that by simply incorporating two photon-absorbing channels, rather than only one, the regulation of energy flow emerges naturally within the photocell.
The basic operating principle is that one channel absorbs at a wavelength for which the average input power is high, while the other absorbs at low power. The photocell switches between high and low power to convert varying levels of solar power into a steady-state output.
When Gabor's team applied these simple models to the measured solar spectrum on Earth's surface, they discovered that the absorption of green light, the most radiant portion of the spectrum per unit wavelength, provides no regulatory benefit and should therefore be avoided. They systematically optimized the photocell parameters to reduce solar energy fluctuations, and found that the absorption spectrum looks nearly identical to the absorption spectrum observed in photosynthetic green plants.
The findings led the researchers to propose that natural regulation of energy they found in the quantum heat engine photocell may play a critical role in the photosynthesis in plants, perhaps explaining the predominance of green plants on Earth.
Other researchers have recently found that several molecular structures in plants, including chlorophyll a and b molecules, could be critical in preventing the accumulation of excess in plants, which could kill them. The UC Riverside researchers found that the molecular structure of the quantum heat engine photocell they studied is very similar to the structure of photosynthetic molecules that incorporate pairs of chlorophyll.
The hypothesis set out by Gabor and his team is the first to connect quantum mechanical structure to the greenness of plants, and provides a clear set of tests for researchers aiming to verify natural regulation. Equally important, their design allows regulation without active input, a process made possible by the photocell's quantum mechanical structure.

 The paper is called "Natural Regulation of Energy Flow in a Green Quantum Photocell.

credit; Sean Nealon
scientists find that Solar cells can be made with tin instead of lead

scientists find that Solar cells can be made with tin instead of lead

,

Solar power could become cheaper and more widespread
Credit: University of Warwick
A breakthrough in solar power could make it cheaper and more commercially viable, thanks to research at the University of Warwick.
In a paper published in Nature Energy, Dr Ross Hatton, Professor Richard Walton and colleagues, explain how solar cells could be produced with tin, making them more adaptable and simpler to produce than their current counterparts.
Solar cells based on a class of semiconductors known as lead perovskites are rapidly emerging as an efficient way to convert sunlight directly into electricity. However, the reliance on lead is a serious barrier to commercialisation, due to the well-known toxicity of lead.
Dr Ross Hatton and colleagues show that perovskites using tin in place of lead are much more stable than previously thought, and so could prove to be a viable alternative to lead perovskites for solar cells.
Lead-free cells could render cheaper, safer and more commercially attractive - leading to it becoming a more prevalent source of energy in everyday life.
This could lead to a more widespread use of solar power, with potential uses in products such as laptop computers, mobile phones and cars.
The team have also shown how the device structure can be greatly simplified without compromising performance, which offers the important advantage of reduced fabrication cost.
Dr Hatton comments that there is an ever-pressing need to develop renewable sources of energy:
"It is hoped that this work will help to stimulate an intensive international research effort into lead-free perovskite solar cells, like that which has resulted in the astonishingly rapid advancement of perovskite solar cells.
"There is now an urgent need to tackle the threat of climate change resulting from humanity's over reliance on fossil fuel, and the rapid development of new solar technologies must be part of the plan."
Perovskite solar cells are lightweight and compatible with flexible substrates, so could be applied more widely than the rigid flat plate silicon that currently dominate the photovoltaics market, particularly in consumer electronics and transportation applications.
The paper, 'Enhanced Stability and Efficiency in Hole-Transport Layer Free CsSnI3 Perovskite Photovoltaics', is published in Nature Energy, and is authored by Dr Ross Hatton, Professor Richard Walton and PhD student Kenny Marshall in the Department of Chemistry, along with Dr Marc Walker in the Department of Physics.

2.5 billion-year-old fossils of bacteria that predate the formation of oxygen

2.5 billion-year-old fossils of bacteria that predate the formation of oxygen


Life before oxygen
A microscopic image of 2.5 billion-year-old sulfur-oxidizing bacterium. Credit: Andrew Czaja, UC assistant professor of geology
Somewhere between Earth's creation and where we are today, scientists have demonstrated that some early life forms existed just fine without any oxygen.
While researchers proclaim the first half of our 4.5 billion-year-old planet's life as an important time for the development and evolution of early bacteria, evidence for these life forms remains sparse including how they survived at a time when oxygen levels in the atmosphere were less than one-thousandth of one percent of what they are today.
Recent geology research from the University of Cincinnati presents new evidence for bacteria found fossilized in two separate locations in the Northern Cape Province of South Africa.
"These are the oldest reported fossil sulfur bacteria to date," says Andrew Czaja, UC assistant professor of geology. "And this discovery is helping us reveal a diversity of life and ecosystems that existed just prior to the Great Oxidation Event, a time of major atmospheric evolution."
The 2.52 billion-year-old sulfur-oxidizing bacteria are described by Czaja as exceptionally large, spherical-shaped, smooth-walled microscopic structures much larger than most modern bacteria, but similar to some modern single-celled organisms that live in deepwater sulfur-rich ocean settings today, where even now there are almost no traces of oxygen.
Life before oxygen
UC Professor Andrew Czaja indicates the layer of rock from which fossil bacteria were collected on a 2014 field excursion near the town of Kuruman in the Northern Cape Province of South Africa. Credit: Aaron Satkoski, UWM postdoc on the excursion.
In his research published in the December issue of the journal Geology of the Geological Society of America, Czaja and his colleagues Nicolas Beukes from the University of Johannesburg and Jeffrey Osterhout, a recently graduated master's student from UC's department of geology, reveal samples of bacteria that were abundant in deep water areas of the ocean in a geologic time known as the Neoarchean Eon (2.8 to 2.5 billion years ago).
"These fossils represent the oldest known organisms that lived in a very dark, deep-water environment," says Czaja. "These bacteria existed two billion years before plants and trees, which evolved about 450 million years ago. We discovered these microfossils preserved in a layer of hard silica-rich rock called chert located within the Kaapvaal craton of South Africa."
With an atmosphere of much less than one percent oxygen, scientists have presumed that there were things living in deep water in the mud that didn't need sunlight or oxygen, but Czaja says experts didn't have any direct evidence for them until now.
Czaja argues that finding rocks this old is rare, so researchers' understanding of the Neoarchean Eon are based on samples from only a handful of geographic areas, such as this region of South Africa and another in Western Australia.

According to Czaja, scientists through the years have theorized that South Africa and Western Australia were once part of an ancient supercontinent called Vaalbara, before a shifting and upending of tectonic plates split them during a major change in the Earth's surface.
Based on radiometric dating and geochemical isotope analysis, Czaja characterizes his fossils as having formed in this early Vaalbara supercontinent in an ancient deep seabed containing sulfate from continental rock. According to this dating, Czaja's fossil bacteria were also thriving just before the era when other shallow-water bacteria began creating more and more oxygen as a byproduct of photosynthesis.
"We refer to this period as the Great Oxidation Event that took place 2.4 to 2.2 billion years ago," says Czaja.
Life before oxygen
Microstructures here have physical characteristics consistent with the remains of compressed coccodial (round) bacteria microorganisms. Credit: Andrew Czaja, permission to publish by Geological Society of America
Early recycling
Czaja's fossils show the Neoarchean bacteria in plentiful numbers while living deep in the sediment. He contends that these early bacteria were busy ingesting volcanic hydrogen sulfide—the molecule known to give off a rotten egg smell—then emitting sulfate, a gas that has no smell. He says this is the same process that goes on today as modern bacteria recycle decaying organic matter into minerals and gases.
"The waste product from one [bacteria] was food for the other," adds Czaja.
"While I can't claim that these early bacteria are the same ones we have today, we surmise that they may have been doing the same thing as some of our current bacteria," says Czaja. "These early bacteria likely consumed the molecules dissolved from sulfur-rich minerals that came from land rocks that had eroded and washed out to sea, or from the volcanic remains on the ocean's floor.
There is an ongoing debate about when sulfur-oxidizing bacteria arose and how that fits into the earth's evolution of life, Czaja adds. "But these fossils tell us that sulfur-oxidizing were there 2.52 billion years ago, and they were doing something remarkable."

credit; Melanie Schefft
In highly lethal type of leukemia, cancer gene predicts treatment response

In highly lethal type of leukemia, cancer gene predicts treatment response


New research led by Washington University School of Medicine in St. Louis shows that patients with acute myeloid leukemia (AML) whose cancer cells carry TP53 mutations -- a feature that correlates with an extremely poor prognosis -- may live longer if they are treated with decitabine, a less intensive chemotherapy drug. The study's first author, John Welch, M.D., PhD, is pictured with Phillip Houghton, who is being treated for AML. Credit: Washington University
Patients with the most lethal form of acute myeloid leukemia (AML) - based on genetic profiles of their cancers - typically survive for only four to six months after diagnosis, even with aggressive chemotherapy. But new research indicates that such patients, paradoxically, may live longer if they receive a milder chemotherapy drug.
Treatment with the less intensive drug, decitabine, is not a cure. But surprisingly, AML patients whose carried mutations in a nefarious cancer gene called TP53 consistently achieved remission after treatment with decitabine. Their median survival was just over a year.
The study, by a team of scientists at Washington University School of Medicine in St. Louis, is published Nov. 24 in The New England Journal of Medicine.
In AML, treatment involves intensive chemotherapy to try to kill the patient's leukemia cells and put the cancer into remission. If successful, a follow-up bone-marrow transplant can offer a possible cure, but this course of treatment is recommended only for patients with a high risk of relapse because the procedure can cause severe complications, even death.
"What's really unique here is that all the patients in the study with TP53 mutations had a response to decitabine and achieved an initial remission," said the study's senior author, Timothy J. Ley, MD, the Lewis T. and Rosalind B. Apple Professor of Medicine, noting that in AML, TP53 mutations have been correlated with an extremely poor prognosis. "With standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.
"The findings need to be validated in a larger trial," Ley added, "but they do suggest that TP53 mutations can reliably predict responses to decitabine, potentially prolonging survival in this ultra high-risk group of patients and providing a bridge to transplantation in some patients who might not otherwise be candidates."
In an accompanying editorial, Elihu Estey, MD, an AML expert at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center in Seattle, noted that AML is not one disease but many, each driven by different genetic mutations. The results of the current trial, he said, point to the inevitable need to replace large cancer clinical trials evaluating homogeneous drug treatments with smaller trials that involve subgroups of patients, with treatments targeted to their specific mutations.
The current study involved 116 patients treated with decitabine at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, and at the University of Chicago. The patients either had AML - a cancer of the bone marrow - or myelodysplastic syndrome (MDS), a group of blood cancers that often progresses to AML. This year, an estimated 20,000 people living in the U.S. will be diagnosed with AML, and at least 11,000 deaths will be attributed to the disease.
Decitabine often is given to older patients with AML or MDS because it is less toxic than standard chemotherapies. But fewer than half of patients who get the drug achieve an initial remission, so the researchers wanted to determine whether specific mutations in the patients' cancer cells could predict their responses to treatment.
To find out, they sequenced all the genes in patients' cancer cells or analyzed select cancer genes. They also conducted standard tests to look for broken, missing or rearranged chromosomes. Then, the researchers correlated these molecular markers with treatment response to identify subgroups of patients likely to benefit from decitabine.
Among the patients in the study, 46 percent achieved a remission with decitabine. But, remarkably, all 21 patients whose leukemia cells carried TP53 mutations went into remission.
Patients also were likely to respond to decitabine if they were deemed to have an "unfavorable risk" prognosis based on extensive chromosomal rearrangements in their cancer cells; many of these patients also had TP53 mutations. Indeed, 66 percent of patients with an unfavorable risk achieved remission, compared with 34 percent of patients who had more favorable prognoses.
"The challenge with using decitabine has been knowing which patients are most likely to respond," said co-author Amanda Cashen, MD, an associate professor of medicine who led an earlier clinical trial of decitabine in older patients with AML. "The value of this study is the comprehensive mutational analysis that helps us figure out which patients are likely to benefit. This information opens the door to using decitabine in a more targeted fashion to treat not just older patients, but also younger patients who carry TP53 mutations."
First author John Welch, MD, PhD, an assistant professor of medicine, added: "It's important to note that patients with an extremely poor prognosis in this relatively small study had the same survival outcomes as patients facing a better prognosis, which is encouraging. We don't yet understand why patients with TP53 mutations consistently respond to decitabine, and more work is needed to understand that phenomenon."
Responses to decitabine are usually short-lived, however, with remissions typically lasting for about a year. Decitabine does not completely clear all the leukemia cells that carry TP53 mutations, and these cells invariably become resistant to the drug, leading to relapse.
"Remissions with decitabine typically don't last long, and no one was cured with this drug," Ley explained. "But patients who responded to decitabine live longer than what you would expect with aggressive chemotherapy, and that can mean something. Some people live a year or two and with a good quality of life, because the chemotherapy is not too toxic."
Roughly 10 percent of AML patients carry TP53 mutations in their leukemia cells. Among patients in the study with such mutations, median survival was 12.7 months - which is not significantly different from the 15.4 months' survival seen in patients without the mutations - and is longer than the typical four- to six-month survival observed in such patients treated with more aggressive therapies.
Decitabine was approved by the FDA in 2006 as a treatment for MDS, but oncologists often prescribe it off-label as a treatment for AML, particularly in older patients. AML typically strikes in a person's mid-60s; the average age of people in the current study was 74.
"We're now planning a larger trial to evaluate decitabine in AML patients of all ages who carry TP53 mutations," Welch said. "It's exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients."


Cannabinoids control memory through mitochondria

Cannabinoids control memory through mitochondria


Cannabinoids and memory
Few classes of drugs have galvanized the pharmaceutical industry in recent times like the cannabinoids. This class of molecules includes not only the natural forms, but also a vast new treasury of powerful synthetic analogs with up to several hundred times the potency as measured by receptor activity and binding affinity. With the FDA now fast tracking all manner of injectables, topicals, and sprays promising everything from relief of nebulous cancer pain to anti-seizure neuroprotection, more than a few skeptics have been generated.
What inquiring minds really want to know, beyond the thorny issue of how well they actually work, is how do they work at all? If you want to understand what something is doing in the cell, one useful approach is to ask what it does to their mitochondria. With drug companies now drooling over the possibility of targeting drugs and treatments directly to these organelles by attaching mitochondrial localization sequences (MLS) or other handler molecules, answers to this kind of question are now coming into focus.
But even with satisfactory explanations in hand, there would still be one large hurdle standing in the way of cannabinoid medical bliss: Namely, even if a patient can manage to avoid operating vehicles or heavy machinery throughout the course of their treatment, how do they cope with the endemic collateral memory loss these drugs invariably cause?
A recent paper published in Nature neatly ties all these subtleties together, and even suggests a possible way out of the brain fog by toggling the sites of cannabinoid action between mitochondria and other cellular compartments. By generating a panel of cannabinoid receptor and second messenger molecules with and without the appropriate MLS tags or accessory binding proteins, the authors were able to directly link cannabinoid-controlled mitochondrial activity to memory formation.
One confounder in this line of work is that these MLSs are very fickle beasts. The 22 or so leader amino acids that make up their 'code' is not a direct addresses in any sense. While the consensus sequences that localize protease action or sort nuclear, endoplasmic reticulum, and plasma membrane proteins generally contain clearly recognizable motifs, any regularities in the MLSs have only proven visible to a computer. That is not to say that MLSs are fictions—they clearly do work—but their predictable action is only witnessed whole once their 3-dimensional vibrating structures are fully-conformed.
The authors availed themselves of two fairly sophisticated programs called Mitoprot and PSQRT to remove any guesswork in identifying a potential MLS in CN1 cannabinoid receptors. CN1s had been previously associated by immunohistochemical methods to what we might call the mitochondrial penumbra, but their presence there may have been purely incidental. This in silico analysis theoretically confirmed the presence of a putative MLS in CB1 and encouraged them to carry out further manipulations of this pathway.
Namely, the researchers took a mouse with the mitochondrial mtCB1 receptor knocked out, and then added modified versions back using viral vectors. When they applied the synthetic cannabinoid ligands (known as WIN55,212 and HU210 ) they found that mitochondrial respiration and mobility, and subsequently memory formation, remained largely intact in animals without the MLS in their receptor.
The researchers were then able to look further downstream using the same general strategy of controlling localization of the second messenger molecule protein kinase A (PKA). By fusing a constitutively active mutant form of PKA to an MLS and putting it inside using an adenovirus they were able to trace the signal cascade into the heart of the complex I of the respiratory chain.
The presence and origin of full G-protein receptor signal pathways in mitochondria is now more than just an academic question. Exactly how retroviruses and other molecular agents of sequence modification managed to re-jigger gene duplicated backups of proteins like CN1 to add alternatively spliced MLS tags is still shrouded in mystery.
Our ability to now harness these same slow evolutionary processes in real time, and bend them to our needs, will undoubtedly have implication well beyond the cannabinoid market. Together the results above suggest the tantalizing possibility of preserving some of the desired benefits of while eliminating the unintended consequences like memory loss or full blown amnesia.

credit; John Hewitt report
New 'smart metal' technology to keep bridge operational in next big quake

New 'smart metal' technology to keep bridge operational in next big quake


A bridge that bends in an strong earthquake and not only remains standing, but remains usable is making its debut in its first real-world application as part of a new exit bridge ramp on a busy downtown Seattle highway.
"We've tested new materials, memory retaining metal rods and flexible concrete composites, in a number of bridge model studies in our large-scale shake table lab, it's gratifying to see the applied for the first time in an important setting in a seismically active area with heavy traffic loads," Saiid Saiidi, civil engineering professor and researcher at the University of Nevada, Reno, said. "Using these materials substantially reduces damage and allows the bridge to remain open even after a strong earthquake."
Saiidi, who pioneered this technology, has built and destroyed, in the lab, several large-scale 200-ton bridges, single bridge columns and concrete abutments using various combinations of innovative materials, replacements for the standard steel rebar and concrete materials and design in his quest for a safer, more resilient infrastructure.
"We have solved the problem of survivability, we can keep a bridge usable after a ," Saiidi said. "With these techniques and materials, we will usher in a new era of super earthquake-resilient structures."
The University partnered with the Washington Department of Transportation and the Federal Highway Administration to implement this new technology on their massive Alaska Way Viaduct Replacement Program, the centerpiece of which is a two-mile long tunnel, but includes 31 separate projects that began in 2007 along the State Route 99 corridor through downtown Seattle.
"This is potentially a giant leap forward," Tom Baker, bridge and structures engineer for the Washington State Department of Transportation, said. "We design for no-collapse, but in the future, we could be designing for no-damage and be able to keep bridges open to emergency vehicles, commerce and the public after a strong quake."
Modern bridges are designed to not collapse during an earthquake, and this new technology takes that design a step further. In the earthquake lab tests, bridge columns built using memory-retaining nickel/titanium rods and a flexible concrete composite returned to their original shape after an earthquake as strong as a magnitude 7.5.
"The tests we've conducted on 4-span bridges leading to this point aren't possible anywhere else in the world than our large-scale structures and earthquake engineering lab," Saiidi said. "We've had great support along the way from many state highway departments and funding agencies like the National Science Foundation, the Federal Highway Administration and the U.S. Department of Transportation. Washington DOT recognized the potential of this technology and understands the need to keep infrastructure operating following a large earthquake."
In an experiment in 2015, featured in a video, one of Saiidi's 's moved more than six inches off center at the base and returned to its original position, as designed, in an upright and stable position. Using the computer-controlled hydraulics, the earthquake engineering lab can increase the intensity of the recorded . Saiidi turned the dial up to 250 percent of the design parameters and still had excellent results.
"It had an incredible 9 percent drift with little damage," Saiidi said.
The Seattle off-ramp with the innovative columns is currently under construction and scheduled for completion in spring 2017. After the new SR 99 tunnel opens, this ramp, just south of the tunnel entrance, will take northbound drivers from SR 99 to Seattle's SODO neighborhood.
A new WSDOT video describes how this innovative technology works.
"Dr. Saiidi sets the mark for the level of excellence to which the College of Engineering aspires," Manos Maragakis, dean of the University's College of Engineering, said. "His research is original and innovative and has made a seminal contribution to seismic safety around the globe."
Researchers show how a targeted drug overcomes suppressive immune cells

Researchers show how a targeted drug overcomes suppressive immune cells


Ludwig researchers show how a targeted drug overcomes suppressive immune cells
Jedd Wolchok is the Director of the Ludwig Collaborative Laboratory at Memorial Sloan Kettering Cancer Center. Credit: Ludwig Cancer Research
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body's immune system from attacking tumors. The researchers also establish that it is these suppressive cells that interfere with the efficacy of immune checkpoint inhibitors. This class of immunotherapies lifts the brakes that the body imposes on the immune system's T cells to unleash an attack on cancer cells.
"Though checkpoint inhibitors have durable effects when they work, not all patients respond to the treatment," says Taha Merghoub, an investigator at the Ludwig Memorial Sloan Kettering Collaborative Laboratory who led the study with Director Jedd Wolchok. "Part of the reason for this is that some tumors harbor tumor-associated myeloid cells, or TAMCs, that prevent T cells from attacking tumor cells."
In a study published online today in Nature, Merghoub and his team used mouse models of cancer to show that the effects of TAMCs can be reversed by an appropriately targeted therapy.
To show that TAMCs were indeed involved in resistance to checkpoint blockade, the researchers used a specific growth stimulant to increase their number in melanoma tumors to create a suitable model for their studies. They found that this made the tumors less susceptible to checkpoint blockade.
"We were able to make a tumor that was not rich in immune suppressing myeloid cells into one that was," says Merghoub.
Having established a link between TAMCs and checkpoint inhibitor resistance, the researchers next set out to test the hypothesis that blocking immune suppressor cell activity would improve immunotherapy response. To do this, they used an experimental drug manufactured by Infinity Pharmaceuticals called IPI-549. The drug, which is available for clinical use, blocks a molecule in the suppressor cells called PI3 kinase-gamma. Blocking this molecule changes the balance of these immune suppressor cells in favor of more immune activation.
"We effectively reprogrammed the TAMCs, turning them from bad guys into good guys," Merghoub said.
IPI-549 dramatically improved responses to immune checkpoint blockade (ICB) therapy for tumors with high concentrations of TAMCs. When checkpoint inhibitors were administered to mice with suppressed tumors, only 20% of the animals underwent complete remission. When the same drugs were administered with IPI-549, that number jumped to 80%. IPI-549 provided no benefit to tumors lacking the suppressor cells.
Merghoub and his team also showed that tumors that were initially sensitive to checkpoint inhibitors were rendered unresponsive when their TAMC concentrations were boosted with growth stimulants.
Taken together, these results indicate that TAMCs promote resistance to checkpoint inhibitors and that IPI-549 can selectively block these cells, thereby overcoming their resistance.
Merghoub said the findings help pave the way for a precision medicine approach to immunotherapy that will allow cancer treatments to be tailored to a patient's particular tumor profile. "We can now potentially identify patients whose tumors possess immune suppressor cells and add a drug to their treatment regimen to specifically disarm them," he added.
IPI-549 is currently undergoing a Phase I trial in the United States to assess its safety when administered alone and in combination with the FDA-approved checkpoint inhibitor drug nivolumab (Opdivo).
Tasting and chewing explored in virtual reality

Tasting and chewing explored in virtual reality


Tasting and chewing explored in virtual reality
Virtual reality technology has you thinking you are doing many things, but there is much uncharted territory in eating virtually.
Imagine what the tourism industry could do with VR technology extending sensory stimulation beyond the eyes and ears. Imagine inviting prospective restaurant clients in virtual reality mode to the meat, fish and chicken specialties, pizza or chocolate cakes. Imagine any number of applications where the sensory experience in virtual reality expands.
Scientists are focusing on VR technology that can fool you into thinking you are tasting food that is not of course really there. Researchers from Singapore and another team from Japan have their own studies that explore the realm of tasting and even chewing.
Vlad Dudau, Neowin, said these explorers managed to replicate the tastes and textures of different foods.
A recent conference in Japan on user interface was given much "food" tech for thought.
The work titled "Virtual Sweet: Simulating Sweet Sensation Using Thermal Stimulation on the Tip of the Tongue," explored what it is like to be tasting sweet food virtually.
"Being a pleasurable sensation, sweetness is recognized as the most preferred sensation among the five primary taste sensations. In this paper, we present a novel method to virtually simulate the sensation of sweetness by applying thermal stimulation to the tip of the human tongue. To digitally simulate the sensation of sweetness, the system delivers rapid heating and cooling stimuli to the tongue via a 2x2 grid of Peltier elements. To achieve distinct, controlled, and synchronized temperature variations in the stimuli, a control module is used to regulate each of the Peltier elements. Results from our preliminary experiments suggest that the participants were able to perceive mild sweetness on the tip of their tongue while using the proposed system."
Nimesha Ranasinghe and Ellen Yi-Luen Do of the National University of Singapore are the two explorers. This is a device where changes in temperature serve to mimic the sensation of sweetness on the tongue.
Victoria Turk in New Scientist wrote about what their technology does: "The user places the tip of their tongue on a square of thermoelectric elements that are rapidly heated or cooled, hijacking thermally sensitive neurons that normally contribute to the sensory code for taste."
MailOnline described it as a "virtual sweetness instrument" which makes use of "a grid of four elements which generate temperature changes of 5°C in a few seconds. "When applied to the tip of the tongue, said the report, "the temperature change results in a virtual sweet sensation." A 9V battery is put to use. Results: Out of 15 people, eight registered a very mild sweet taste, said MailOnline.

Applications could include a taste-enhancing technology for dieters. Dr Ranashinghe told MailOnline: 'We believe this will especially helpful for the people on restricted diets for example salt (hypertension and heart problems) and sugar (diabetics)."
New Scientist said Ranasinghe and Do could see a system like this embedded in a glass or mug to make low sugar drinks taste sweeter.
Another group from the University of Tokyo is using electrodes to stimulate the jaw muscles. Tokyo Researchers Arinobu Niijima and Takefumi Ogawa are reporting results from an electrical muscle stimulation (EMS) test of jaw movements in chewing.
"We propose Electric Food Texture System, which can present virtual food texture such as hardness and elasticity by electrical muscle stimulation (EMS) to the masseter muscle," said the researchers in a video posted last month on their work, "Study on Control Method of Virtual Food Texture by Electrical Muscle Stimulation."
Dudau in Neowin described their experiment, where "scientists attached electrodes to jaw muscles and managed to simulate the sensation of biting into different materials. For example, by varying the electrical stimulation, users reported that while eating a real cookie, it felt like biting into something soft, or chewing something hard alternatively."
Turk in New Scientist also talked about the Tokyo team who presented "a device that uses electricity to simulate the experience of chewing foods of different textures. Arinobu Niijima and Takefumi Ogawa's Electric Food Texture System also uses electrodes, but not on the tongue, instead they place them on the masseter muscle – a muscle in the jaw used for chewing – to give sensations of hardness or chewiness as a user bites down. 'There is no food in the mouth, but users feel as if they are chewing some food due to haptic feedback by electrical muscle stimulation,' says Niijima."
Getting into technical details, MailOnline said "By delivering short pulses of between 100 to 250 Hz they were able to stimulate the masseter muscles, used to chew solid foods."
So if the 'sugar' researchers were looking at taste sensation, these researchers were looking at food texture. They said, "In this paper, we investigated the feasibility to control virtual food texture by EMS."
The researchers said on their video page, "We conducted an experiment to reveal the relationship of the parameters of EMS and those of virtual food texture. The experimental results show that the higher strength of EMS is, the harder virtual food texture is, and the longer duration of EMS is, the more elastic virtual food texture is."
If at higher frequency, the sensation was that of eating tougher, chewy food but a longer pulse simulated a more elastic texture.
 Statistics in to the quantum domain

Statistics in to the quantum domain


quantum change point
In the quantum change point problem, a quantum source emits particles that are received by a detector. At some unknown point, a change occurs in the state of the particles being emitted. Physicists have found that global measurement methods, which use quantum repeaters, outperform all classical measurement methods for accurately identifying when the change occurred. Credit: Sentis et al. ©2016 American Physical Society
(Phys.org)—The change point problem is a concept in statistics that pops up in a wide variety of real-world situations, from stock markets to protein folding. The idea is to detect the exact point at which a sudden change has occurred, which could indicate, for example, the trigger of a financial crisis or a misfolded protein step.
Now in a new paper published in Physical Review Letters, physicists Gael Sentís et al. have taken the change point problem to the quantum domain.
"Our work sets an important landmark in by porting a fundamental tool of classical statistical analysis into a fully quantum setup," Sentis, at the University of the Basque Country in Bilbao, Spain, told Phys.org.
"With an ever-growing number of promising applications of quantum technologies in all sorts of data processing, building a quantum statistical toolbox capable of dealing with real-world practical issues, of which change point detection is a prominent example, will be crucial. In our paper, we demonstrate the working principles of quantum change point detection and facilitate the grounds for further research on change points in applied scenarios."
Although change point problems can deal with very complex situations, they can also be understood with the simple example of playing a game of Heads or Tails. This game begins with a fair coin, but at some unknown point in the game the coin is switched with a biased one. By statistically analyzing the results of each coin toss from the beginning, it's possible to determine the most likely point at which the coin was switched.
Extending this problem to the quantum realm, the physicists looked at a quantum device that emits particles in a certain state, but at some unknown point the source begins to emit particles in a different state. Here the quantum change point problem can be understood as a problem of discrimination, since determining when the change in the source occurred is the same as distinguishing among all possible sequences of quantum states of the emitted particles.
Physicists can determine the change point in this situation in two different ways: either by measuring the state of each particle as soon as it arrives at the detector (a "local measurement"), or by waiting until all of the particles have reached the detector and making a measurement at the very end (a "global measurement").
Although the local measurement method sounds appealing because it can potentially detect the change point as soon as it occurs without waiting for all of the particles to be emitted, the researchers found that global measurements outperform even the best local measurement strategies.
The "catch" is that global measurements are more difficult to experimentally realize and require a to store the quantum states as they arrive at the detector one by one. The local measurement methods don't require a quantum memory, and instead can be implemented using much simpler devices in sequence. Since global detection requires a quantum memory, the results show that change point detection is another of the many problems for which quantum methods outperform all classical ones.
"We expected that would help, as coherent quantum operations tend to exploit genuinely quantum resources and generally outperform local operations in many information processing tasks," Sentis said. "However, this is a case-dependent advantage, and sometimes sophisticated and clever local strategies are enough to cover the gap. The fact that here there is a finite performance gap says something fundamental about change point detection in quantum scenarios."
The results have potential applications in any situation that involves analyzing data collected over time. Change point detection is also often used to divide a data sample into subsamples that can then be analyzed individually.
"The ability to accurately detect quantum change points has immediate impact on any process that requires careful control of quantum information," Sentis said. "It can be considered a quality testing device for any information processing task that requires (or produces) a sequence of identical quantum states. Applications may range from probing quantum optical fibers to boundary detection in solid state systems."
In the future, the researchers plan on exploring the many applications of quantum change point detection.
"We plan on extending our theoretical methods to deal with more realistic scenarios," Sentis said. "The possibilities are countless. A few examples of generalizations we are exploring are multiple change points, noisy quantum states, and detection of change points in optical setups."
Researchers discover way to inhibit major cancer gene

Researchers discover way to inhibit major cancer gene


Researchers discover way to inhibit major cancer gene

Researchers at the University of Illinois at Chicago have identified a new way to block the action of genetic mutations found in nearly 30 percent of all cancers.
Mutations in genes for the RAS family of proteins are present in nearly 90 percent of pancreatic cancers and are also highly prevalent in colon cancer, lung cancer and melanoma, the most dangerous kind of skin cancer.
The group of proteins include three members, K-RAS, H-RAS and N-RAS.
The prevalence of RAS mutations in human cancers and the dependence of tumors on RAS for survival has made a RAS a prime target for cancer research and drug discovery. Scientists and drug developers have long studied RAS oncogenes hoping to find a new treatment for cancer, but they have not yet been able to identify drugs that safely inhibit the oncogene's activity.
John O'Bryan, associate professor of pharmacology in the UIC College of Medicine, led a team of researchers that took a different approach to studying RAS, and discovered that a synthetic binding protein they call "NS1 monobody," which they created in the lab, can block the activity of the RAS proteins.
"We did not look for a drug or specifically for an inhibitor," said O'Bryan, who is also a member of the University of Illinois Cancer Center and holds an appointment at the Jesse Brown VA Medical Center in Chicago. "We used monobody technology, a type of protein-engineering technology, to identify regions of RAS that are critical for its function."
Unlike conventional antibodies, monobodies are not dependent on their environment and can be readily used as genetically encoded inhibitors, O'Bryan said.
"The beauty of the technology is that when a monobody binds a protein, it usually works as an inhibitor of that protein," he said.
Monobodies were developed by Shohei Koide, a co-author on the study who is professor of biochemistry and molecular pharmacology at New York University. They have been used to target a diverse array of proteins that include enzymes and receptors.
The researchers found that the NS1 monobody binds to an area of the RAS protein molecule that was not previously known to be important for its oncogenic activity. NS1 strongly inhibits oncogenic K-RAS and H-RAS function by blocking the ability of the protein to interact with an identical one to form a molecular pair. NS1 does not affect N-RAS.
O'Bryan says the findings, published in the journal Nature Chemical Biology, provide important insight into long-standing questions about how RAS proteins function in cells. These insights may help guide the development of new therapeutic approaches to treating cancer by interfering with mutant RAS function in cancer cells.
"Development of effective RAS inhibitors represents a 'holy grail' in cancer biology," O'Bryan said. "We now have a powerful tool we can use to further probe RAS function. While future studies and trials are needed before these findings can be leveraged outside the lab, this study provides new insight into how we can potentially inhibit RAS to slow tumor growth."
Lab creates open-source optogenetics hardware, software

Lab creates open-source optogenetics hardware, software


Lab creates open-source optogenetics hardware, software
Rice University’s low-cost, open-source Light Plate Apparatus can easily be used by nonengineers and noncomputer programmers and can be assembled by a nonexpert in one day from components costing less than $150. Credit: Jeff Fitlow/Rice University
Nobody likes a cheater, but Rice University bioengineering graduate student Karl Gerhardt wants people to copy his answers. That's the whole point.
Gerhardt and Rice colleagues have created the first low-cost, easy-to-use hardware platform that biologists who have little or no training in engineering or software design can use to incorporate optogenetics testing in their labs.
Rice's Light Plate Apparatus (LPA) is described in a paper available for free online this week in the open-access journal Scientific Reports. The LPA, which was created in the lab of Jeffrey Tabor, assistant professor of bioengineering, uses open-source hardware and software. The apparatus can deliver two independent light signals to each well in a standard 24-well plate and has sockets that accept LEDs of wavelengths ranging from blue to far red. Total component costs for the LPA are less than $400—$150 for labs with a 3-D printer—and each unit can be assembled and calibrated by a nonexpert in one day.
"Our intent is to bring optogenetics to any researcher interested in using it," said Tabor, whose students created the LPA. In doing so, they found ways to make most of its parts with 3-D printers and also created software called Iris that uses simple buttons and pull-down menus to allow researchers to program the instrument for a wide range of experiments.
Rice bioengineers Karl Gerhardt (left) and Jeffrey Tabor with the Light Plate Apparatus, a low-cost, open-source optogenetics platform. Credit: Jeff Fitlow/Rice University
Optogenetics, which was developed in the past 15 years, involves genetically modifying cells with light-sensing molecules so that light can be used to turn genes and other cellular processes on or off. Its most notable successes have come in neuroscience following the invention of brain-implantable optical neuro interfaces, which have explored the cells and mechanisms associated with aggression, parenting, drug addiction, mating, same-sex attraction, anxiety, obsessive-compulsive disorders and more.
"Over the past 5-10 years, practically every biological process has been put under optogenetics control," said Gerhardt, who works in Tabor's lab. "The problem is that while everyone has been developing the biological tools to do optogenetics—the light-sensing proteins, gene-expression systems, protein interactions, etc.—outside of neuroscience, no one has really developed good hardware that makes it easy to use those tools."
To demonstrate the broad applicability of LPA, Tabor, Gerhardt and co-authors used the system to perform a series of optogenetics tests on a diverse set of model organisms, including gut bacteria, yeast, mammalian cells and photosynthetic cyanobacteria.
Gerhardt didn't come to Rice intending to invent the world's first easy-to-use optogenetics research platform. A biochemist by training, he initially was interested in simply creating something that would allow him to incorporate optogenetics in his own research. In early 2014, Gerhardt was studying the social amoeba Dictyostelium discoideum. Evan Olson, another Ph.D. student in Tabor's group, had just created the "light tube array," or LTA, an automated system for doing optogenetics on up to 64 test tubes at a time.
Lab creates open-source optogenetics hardware, software
Rice University graduate students Karl Gerhardt (left) and Sebastián Castillo-Hair prepare cell cultures for optogenetics testing with the Light Plate Apparatus, an open-source system they developed with colleagues in the laboratory of Rice’s Jeffrey Tabor, assistant professor of bioengineering. Credit: Jeff Fitlow/Rice University
Unfortunately for Gerhardt, D. discoideum, which biologists commonly call "dicty," prefers to grow on flat surfaces, like Petri dishes and flat-bottomed well plates. Dicty is also sensitive to vibrations and movement. Like dicty, many organisms commonly studied in biology labs, including many animal cell lines and virtually all human cells, require similar conditions.
"I couldn't culture dicty in the LTA, so I built a sort of plate-based version, and I used it for a couple of experiments, but it didn't work very well," Gerhardt said. "Then, some other people in our lab who had training in electrical engineering and Evan, with his physics background, said, 'We can take this version and make it a lot better.'"
Gerhardt said the group kept innovating and coming up with new versions of the hardware. For example, to make it easy to change the wavelength of light, the team incorporated standard sockets so it would be easy to swap out different colored LEDs. They also added a low-cost microcontroller with an SD card reader, drivers capable of producing more than 4,000 levels of light intensity and millisecond time control.
"We got more and more ambitious in terms of the features we wanted to add, and now we're on version three or four of the hardware," he said. "Then Lucas (Hartsough), Brian (Landry) and Felix (Ekness), members of our group who had expertise in programming and website design, said, 'We'll make the software,' and that's where Iris came from."
Rice University graduate student Sebastián Castillo-Hair conducts tests with the Light Plate Apparatus, an open-source optogenetics research platform developed in the laboratory of Rice’s Jeffrey Tabor, assistant professor of bioengineering. Credit: Jeff Fitlow/Rice University
Iris makes use of a graphical user interface to allow people without specialized computer training to easily program experiments for the LPA.
"Programming is a major barrier for some biologists who want to work with this kind of hardware," Gerhardt said. "Optogenetics hardware, most of the time, requires someone with programming experience who can go into the command line and write code. We wanted to eliminate that barrier."
To simplify the process for getting started with LPA, Tabor and Gerhardt have published all the software, design files and specifications for the system on GitHub, a site that caters to the do-it-yourself community by making it easy to create, share and distinguish different versions of software and files for open-source platforms like LPA.
Gerhardt said at least a half-dozen research groups began making LPAs after an early version of the paper was posted on a biology preprint server, and he hopes many more begin using it now that the Scientific Reports paper has been published.
"I hope this becomes the standard format for doing general optogenetics experiments, especially for people on the biology end of the spectrum who would never think about building their own hardware," Gerhardt said. "I hope they'll see this and say, 'OK. We can do optogenetics now.'"

Translate

Ads